相关实验视频

Updated: Feb 17, 2026

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines

Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines

Published on: June 23, 2019

基于伊米达的阿波-IDO1抑制剂的发现:合理设计,合成和生物评估

Jin-Hong Wu¹, Yue-Hui Xing², Xing-Hua Wang²

¹School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China; Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China.

Bioorganic & medicinal chemistry letters

|February 15, 2026

概括

研究人员开发了新的基于伊米达的抑制剂,以向底胺2,3-二氧化原酶1 (IDO1). 最强效的化合物YC-16在各种组织中有效地抑制了apo-IDO1而没有显著的毒性,提供了一个有前途的治疗途径.

科学领域:

药用化学医学化学
酶抑制可以抑制酶.
药物发现药物发现药物发现

背景情况:

氨酸二氧化酶1 (IDO1) 是托代谢中的一个关键酶,涉及免疫调节和癌症.
针对IDO1,特别是它的apo形式,为各种疾病提供了治疗策略.
现有的IDO1抑制剂往往缺乏特异性或表现出细胞毒性.

研究的目的:

设计,合成和评估基于伊米达的新型Apo-IDO1抑制剂.
为了确定具有有利的药理动力学特性的强效和选择性抑制剂.
为了阐明化合物的作用机制.

主要方法:

合理的药物设计基于一个三元制药模型.
合成基于伊米达的化合物.
在体外生物评估,包括IC50测定和细胞毒性测定.
结构与活动关系 (SAR) 研究.
机制研究以确定抑制的模式.

主要成果:

系统的SAR研究导致了YC-16的鉴定,YC-16是一种强大的Apo-IDO1抑制剂,IC50为0.18±0.01μM.
YC-16表现出广泛的组织选择性,没有显著的细胞毒性.
机理学研究表明,YC-16通过血红素移位和直接结合来抑制apo-IDO1.
YC-16 作为一个全组织的 Apo-IDO1 抑制剂,而不改变 IDO1 的表达.

结论:

YC-16是一种高度强效和选择性的全组织Apo-IDO1抑制剂.
基于伊米达的支架为开发新的IDO1向治疗提供了有希望的基础.
对YC-16的进一步结构优化可能会导致先进的候选药物.

关键词:

这是Apo-IDO1抑制剂.血红细胞的移位血红细胞的移位伊米达 (Imidazole) 是一种药物.全组织抑制的抑制.结构与活动关系 (SAR)

更多相关视频

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Synthesis of Antiviral Tetrahydrocarbazole Derivatives by Photochemical and Acid-catalyzed C-H Functionalization via Intermediate Peroxides CHIPS

Synthesis of Antiviral Tetrahydrocarbazole Derivatives by Photochemical and Acid-catalyzed C-H Functionalization via Intermediate Peroxides CHIPS

Published on: June 20, 2014

相关概念视频

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Aryldiazonium Salts to Azo Dyes: Diazo Coupling

Aryldiazonium Salts to Azo Dyes: Diazo Coupling

The reaction of weakly electrophilic aryldiazonium (also called arenediazonium) salts with highly activated aromatic compounds leads to the formation of products with an —N=N— link, called an azo linkage. This reaction, presented in Figure 1, is known as diazo coupling and occurs without the loss of the nitrogen atoms of the aryldiazonium salt. Highly activated aromatic compounds such as phenols or arylamines favor the diazo coupling reaction. The coupling generally occurs at the para...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...